An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial.

Trial Profile

An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms RIALTO
  • Sponsors Bayer
  • Most Recent Events

    • 13 Jun 2017 Planned End Date changed from 28 Dec 2017 to 28 Dec 2019.
    • 13 Jun 2017 Planned primary completion date changed from 28 Dec 2017 to 28 Dec 2019.
    • 21 Jul 2016 Planned number of patients changed from 14 to 25.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top